Abstract
Coronavirus disease 2019 (COVID-19) outcomes are linked to host immune responses and may be affected by antiviral therapy. We investigated antibody and cytokine responses in ACTT-1 study participants enrolled at our center. We studied serum specimens from 19 hospitalized adults with COVID-19 randomized to treatment with remdesivir or placebo. We assessed severe acute respiratory syndrome coronavirus 2 antibody responses and identified cytokine signatures, using hierarchical clustering. We identified no clear immunologic trends attributable to remdesivir treatment. Seven participants were initially seronegative at study enrollment, and all 4 deaths occurred in this group with more recent symptom onset. We identified 3 dominant cytokine signatures, demonstrating different disease trajectories.
Keywords: ACTT-1; COVID-19; cytokine; neutralization; remdesivir; serology; trajectory.
【저자키워드】 COVID-19, serology, neutralization, Remdesivir, cytokine, trajectory, ACTT-1, 【초록키워드】 Treatment, coronavirus disease, antiviral therapy, Coronavirus disease 2019, coronavirus, Hospitalized, serology, antibody, neutralization, Antibody Response, Remdesivir, cytokine, outcome, severe acute respiratory syndrome Coronavirus, Randomized, serum, Antibody responses, Host immune response, immune responses, Clustering, death, trajectory, Placebo, respiratory, seronegative, cytokine response, hierarchical clustering, symptom onset, Hierarchical, acute respiratory syndrome, acute respiratory syndrome coronavirus 2, study enrollment, specimen, participant, host immune responses, dominant, disease trajectories, enrolled, affected, occurred, investigated, study participant, with COVID-19, 【제목키워드】 Profiling, early disease,